Plasma levels of soluble AβPPβ as a biomarker for Alzheimer's disease with dementia

Panagiotis Alexopoulos, Nathalie Thierjung, Polychronis Economou, Lukas Werle, Felix Buhl, Simone Kagerbauer, Anastasios D. Papanastasiou, Timo Grimmer, Philippos Gourzis, Achim Berthele, Bernhard Hemmer, Hubert Kübler, Jan Martin, Antonios Politis, Robert Perneczky

Research output: Contribution to journalArticlepeer-review


Cost- and time-effective markers of Alzheimer's disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N=33) are significantly lower (p<0.01) than those of cognitively healthy elderly individuals without AD (N=39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate.

Original languageEnglish (US)
Pages (from-to)83-90
Number of pages8
JournalJournal of Alzheimer's Disease
Issue number1
StatePublished - 2019


  • Biomarker candidate
  • NIA-AA research framework diagnostic criteria
  • soluble amyloid-β protein precursor β

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health


Dive into the research topics of 'Plasma levels of soluble AβPPβ as a biomarker for Alzheimer's disease with dementia'. Together they form a unique fingerprint.

Cite this